BioLife Solutions (BLFS) Competitors

$21.55 +0.46 (+2.18%)

Closing price 04:00 PM Eastern

Extended Trading

$21.56 +0.00 (+0.02%)

As of 05:44 PM Eastern

BLFS vs. IRTC, TMDX, MMED, LIVN, and LQDA

Should you be buying BioLife Solutions stock or one of its competitors? The main competitors of BioLife Solutions include iRhythm Technologies (IRTC), TransMedics Group (TMDX), MiniMed Group (MMED), LivaNova (LIVN), and Liquidia (LQDA). These companies are all part of the "medical equipment" industry.

How does BioLife Solutions compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

: iRhythm Technologies has a net margin of -3.53% compared to BioLife Solutions' net margin of -4.50%. BioLife Solutions' return on equity of 1.71% beat iRhythm Technologies' return on equity.
Company Net Margins Return on Equity Return on Assets
iRhythm Technologies -3.53% -10.26% -1.39%
BioLife Solutions -4.50% 1.71% 1.54%
: iRhythm Technologies currently has a consensus target price of $193.38, indicating a potential upside of 63.73%. BioLife Solutions has a consensus target price of $32.00, indicating a potential upside of 48.49%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe iRhythm Technologies is more favorable than BioLife Solutions.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRhythm Technologies
1 Sell rating(s)
1 Hold rating(s)

11 Buy rating(s)

2 Strong Buy rating(s)
2.93
BioLife Solutions
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80
: 93.2% of BioLife Solutions shares are owned by institutional investors. 1.0% of iRhythm Technologies shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: iRhythm Technologies has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500.
: In the previous week, iRhythm Technologies had 35 more articles in the media than BioLife Solutions. MarketBeat recorded 36 mentions for iRhythm Technologies and 1 mentions for BioLife Solutions. iRhythm Technologies' average media sentiment score of 0.43 beat BioLife Solutions' score of 0.34 indicating that iRhythm Technologies is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iRhythm Technologies
8 Very Positive mention(s)
10 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioLife Solutions
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: BioLife Solutions has lower revenue, but higher earnings than iRhythm Technologies. BioLife Solutions is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
iRhythm Technologies $747.14M 5.19 -$44.55M -$0.86 N/A
BioLife Solutions $96.21M 10.95 -$4.59M -$0.11 N/A

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
BioLife Solutions	-4.50%	1.71%	1.54%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
BioLife Solutions	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	8 Very Positive mention(s)	10 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLife Solutions	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	5.19	-$44.55M	-$0.86	N/A
BioLife Solutions	$96.21M	10.95	-$4.59M	-$0.11	N/A

Summary

iRhythm Technologies and BioLife Solutions tied by winning 8 of the 16 factors compared between the two stocks.

How does BioLife Solutions compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

: TransMedics Group has a net margin of 31.43% compared to BioLife Solutions' net margin of -4.50%. TransMedics Group's return on equity of 30.17% beat BioLife Solutions' return on equity.
Company Net Margins Return on Equity Return on Assets
TransMedics Group 31.43% 30.17% 11.39%
BioLife Solutions -4.50% 1.71% 1.54%
: TransMedics Group currently has a consensus target price of $152.33, indicating a potential upside of 60.47%. BioLife Solutions has a consensus target price of $32.00, indicating a potential upside of 48.49%. Given TransMedics Group's higher probable upside, equities research analysts plainly believe TransMedics Group is more favorable than BioLife Solutions.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransMedics Group
0 Sell rating(s)
5 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.58
BioLife Solutions
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80
: 99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: TransMedics Group has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500.
: In the previous week, TransMedics Group had 7 more articles in the media than BioLife Solutions. MarketBeat recorded 8 mentions for TransMedics Group and 1 mentions for BioLife Solutions. TransMedics Group's average media sentiment score of 0.83 beat BioLife Solutions' score of 0.34 indicating that TransMedics Group is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TransMedics Group
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioLife Solutions
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: TransMedics Group has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TransMedics Group $605.49M 5.41 $190.29M $4.90 19.37
BioLife Solutions $96.21M 10.95 -$4.59M -$0.11 N/A

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	31.43%	30.17%	11.39%
BioLife Solutions	-4.50%	1.71%	1.54%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
BioLife Solutions	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLife Solutions	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	5.41	$190.29M	$4.90	19.37
BioLife Solutions	$96.21M	10.95	-$4.59M	-$0.11	N/A

Summary

TransMedics Group beats BioLife Solutions on 13 of the 17 factors compared between the two stocks.

How does BioLife Solutions compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and BioLife Solutions (NASDAQ:BLFS) are both medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

: MiniMed Group has a net margin of 0.00% compared to BioLife Solutions' net margin of -4.50%. BioLife Solutions' return on equity of 1.71% beat MiniMed Group's return on equity.
Company Net Margins Return on Equity Return on Assets
MiniMed Group N/A N/A N/A
BioLife Solutions -4.50% 1.71% 1.54%
: In the previous week, MiniMed Group and MiniMed Group both had 1 articles in the media. BioLife Solutions' average media sentiment score of 0.34 beat MiniMed Group's score of 0.20 indicating that BioLife Solutions is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiniMed Group
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
BioLife Solutions
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: MiniMed Group presently has a consensus target price of $22.45, indicating a potential upside of 92.25%. BioLife Solutions has a consensus target price of $32.00, indicating a potential upside of 48.49%. Given MiniMed Group's stronger consensus rating and higher possible upside, analysts plainly believe MiniMed Group is more favorable than BioLife Solutions.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiniMed Group
0 Sell rating(s)
2 Hold rating(s)

11 Buy rating(s)

0 Strong Buy rating(s)
2.85
BioLife Solutions
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80
: MiniMed Group has higher revenue and earnings than BioLife Solutions.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MiniMed Group $2.99B 1.10 N/A N/A N/A
BioLife Solutions $96.21M 10.95 -$4.59M -$0.11 N/A
: 19.7% of MiniMed Group shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 2.2% of MiniMed Group shares are held by company insiders. Comparatively, 2.2% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
BioLife Solutions	-4.50%	1.71%	1.54%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioLife Solutions	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
BioLife Solutions	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$2.99B	1.10	N/A	N/A	N/A
BioLife Solutions	$96.21M	10.95	-$4.59M	-$0.11	N/A

Summary

BioLife Solutions beats MiniMed Group on 7 of the 12 factors compared between the two stocks.

How does BioLife Solutions compare to LivaNova?

BioLife Solutions (NASDAQ:BLFS) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

: BioLife Solutions has a net margin of -4.50% compared to LivaNova's net margin of -17.46%. LivaNova's return on equity of 16.54% beat BioLife Solutions' return on equity.
Company Net Margins Return on Equity Return on Assets
BioLife Solutions -4.50% 1.71% 1.54%
LivaNova -17.46% 16.54% 7.30%
: BioLife Solutions has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.
: In the previous week, BioLife Solutions and BioLife Solutions both had 1 articles in the media. BioLife Solutions' average media sentiment score of 0.34 beat LivaNova's score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioLife Solutions
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
LivaNova
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: BioLife Solutions presently has a consensus price target of $32.00, indicating a potential upside of 48.49%. LivaNova has a consensus price target of $74.78, indicating a potential upside of 29.85%. Given BioLife Solutions' stronger consensus rating and higher probable upside, equities research analysts clearly believe BioLife Solutions is more favorable than LivaNova.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80
LivaNova
1 Sell rating(s)

2 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.60
: BioLife Solutions has higher earnings, but lower revenue than LivaNova. BioLife Solutions is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLife Solutions $96.21M 10.95 -$4.59M -$0.11 N/A
LivaNova $1.39B 2.28 -$242.47M -$4.46 N/A
: 93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Comparatively, 0.3% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-4.50%	1.71%	1.54%
LivaNova	-17.46%	16.54%	7.30%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
LivaNova	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	10.95	-$4.59M	-$0.11	N/A
LivaNova	$1.39B	2.28	-$242.47M	-$4.46	N/A

Summary

BioLife Solutions beats LivaNova on 11 of the 16 factors compared between the two stocks.

How does BioLife Solutions compare to Liquidia?

BioLife Solutions (NASDAQ:BLFS) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

: 93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: BioLife Solutions has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.
: BioLife Solutions has a net margin of -4.50% compared to Liquidia's net margin of -43.53%. BioLife Solutions' return on equity of 1.71% beat Liquidia's return on equity.
Company Net Margins Return on Equity Return on Assets
BioLife Solutions -4.50% 1.71% 1.54%
Liquidia -43.53% -209.33% -25.32%
: In the previous week, Liquidia had 12 more articles in the media than BioLife Solutions. MarketBeat recorded 13 mentions for Liquidia and 1 mentions for BioLife Solutions. Liquidia's average media sentiment score of 0.59 beat BioLife Solutions' score of 0.34 indicating that Liquidia is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioLife Solutions
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Liquidia
5 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: BioLife Solutions presently has a consensus price target of $32.00, indicating a potential upside of 48.49%. Liquidia has a consensus price target of $43.44, indicating a potential upside of 8.26%. Given BioLife Solutions' stronger consensus rating and higher probable upside, equities research analysts clearly believe BioLife Solutions is more favorable than Liquidia.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLife Solutions
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80
Liquidia
2 Sell rating(s)

1 Hold rating(s)

7 Buy rating(s)

2 Strong Buy rating(s)
2.75
: BioLife Solutions has higher earnings, but lower revenue than Liquidia. BioLife Solutions is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioLife Solutions $96.21M 10.95 -$4.59M -$0.11 N/A
Liquidia $158.32M 22.53 -$68.92M -$0.83 N/A

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-4.50%	1.71%	1.54%
Liquidia	-43.53%	-209.33%	-25.32%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liquidia	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Liquidia	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	10.95	-$4.59M	-$0.11	N/A
Liquidia	$158.32M	22.53	-$68.92M	-$0.83	N/A

Summary

BioLife Solutions beats Liquidia on 9 of the 16 factors compared between the two stocks.

Get BioLife Solutions News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLFS vs. The Competition

Export

Metric	BioLife Solutions	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.03B	$8.14B	$6.24B	$11.86B
Dividend Yield	N/A	2.45%	2.73%	5.21%
P/E Ratio	175.75	119.73	29.04	28.48
Price / Sales	10.95	7.42	477.10	60.43
Price / Cash	92.10	17.32	27.62	36.52
Price / Book	2.79	3.52	9.67	6.67
Net Income	-$4.59M	$223.69M	$3.55B	$332.64M
7 Day Performance	3.11%	0.07%	1.70%	2.01%
1 Month Performance	10.46%	10.31%	5.62%	9.19%
1 Year Performance	-10.95%	0.92%	34.42%	39.59%

BioLife Solutions Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLFS BioLife Solutions	2.9714 of 5 stars	$21.55 +2.2%	$32.00 +48.5%	N/A	$1.03B	$96.21M	175.75	440	Upcoming Earnings
IRTC iRhythm Technologies	2.8774 of 5 stars	$125.96 +3.0%	$202.92 +61.1%	N/A	$4.02B	$747.14M	N/A	2,400	News Coverage Earnings Report Analyst Upgrade
TMDX TransMedics Group	4.6027 of 5 stars	$108.12 -2.5%	$152.33 +40.9%	N/A	$3.83B	$605.49M	22.07	210	News Coverage Earnings Report
MMED MiniMed Group	N/A	$12.92 -2.1%	$22.45 +73.8%	N/A	$3.63B	$2.99B	N/A	8,000
LIVN LivaNova	2.224 of 5 stars	$63.41 -1.2%	$74.78 +17.9%	N/A	$3.51B	$1.39B	N/A	3,300	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLFS) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLife Solutions (BLFS) Competitors

BLFS vs. IRTC, TMDX, MMED, LIVN, and LQDA

How does BioLife Solutions compare to iRhythm Technologies?

Summary

How does BioLife Solutions compare to TransMedics Group?

Summary

How does BioLife Solutions compare to MiniMed Group?

Summary

How does BioLife Solutions compare to LivaNova?

Summary

How does BioLife Solutions compare to Liquidia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLFS vs. The Competition

BioLife Solutions Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLife Solutions (BLFS) Competitors

BLFS vs. IRTC, TMDX, MMED, LIVN, and LQDA

How does BioLife Solutions compare to iRhythm Technologies?

Summary

How does BioLife Solutions compare to TransMedics Group?

Summary

How does BioLife Solutions compare to MiniMed Group?

Summary

How does BioLife Solutions compare to LivaNova?

Summary

How does BioLife Solutions compare to Liquidia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLFS vs. The Competition

BioLife Solutions Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools